Ventyx Biosciences (NASDAQ:VTYX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Ventyx Biosciences (NASDAQ:VTYX) to a hold rating in a research report report published on Saturday.

A number of other equities analysts have also recently issued reports on the company. Canaccord Genuity Group cut Ventyx Biosciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $16.00 to $14.00 in a report on Thursday, January 8th. HC Wainwright downgraded shares of Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 target price on the stock. in a research report on Thursday, January 8th. UBS Group reissued a “neutral” rating and set a $14.00 target price (down from $20.00) on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Lifesci Capital restated a “market perform” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a report on Thursday, January 8th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Eight equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $14.00.

Ventyx Biosciences Price Performance

Shares of Ventyx Biosciences stock opened at $14.00 on Friday. The stock’s 50-day moving average is $13.33 and its 200 day moving average is $8.57. Ventyx Biosciences has a one year low of $0.78 and a one year high of $25.00. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -9.33 and a beta of 1.26.

Insiders Place Their Bets

In other Ventyx Biosciences news, insider John Nuss sold 12,675 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the transaction, the insider owned 489,481 shares in the company, valued at approximately $3,778,793.32. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Raju Mohan sold 47,345 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the transaction, the chief executive officer directly owned 2,372,863 shares in the company, valued at $18,318,502.36. This trade represents a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 14.49% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ventyx Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Arrowpoint Investment Partners Singapore Pte. Ltd. raised its holdings in shares of Ventyx Biosciences by 5.9% in the 4th quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. now owns 28,453 shares of the company’s stock worth $257,000 after acquiring an additional 1,595 shares during the last quarter. Prospera Financial Services Inc boosted its stake in Ventyx Biosciences by 1.2% during the 4th quarter. Prospera Financial Services Inc now owns 151,570 shares of the company’s stock valued at $1,369,000 after purchasing an additional 1,770 shares during the last quarter. Birchview Capital LP increased its holdings in Ventyx Biosciences by 2.0% during the 4th quarter. Birchview Capital LP now owns 100,827 shares of the company’s stock worth $910,000 after purchasing an additional 2,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ventyx Biosciences during the 4th quarter worth approximately $31,000. Finally, Prelude Capital Management LLC raised its stake in shares of Ventyx Biosciences by 35.0% in the third quarter. Prelude Capital Management LLC now owns 21,200 shares of the company’s stock worth $66,000 after purchasing an additional 5,500 shares during the last quarter. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.